Nektar Therapeutics Lessor, Operating Lease, Payment to be Received, Year Five
Nektar Therapeutics (NKTR) had Lessor, Operating Lease, Payment to be Received, Year Five of $1.85 million as of 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Notes › Leases › Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity
us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears · last filed 2025-03-14
- 2024-12-31: Lessor, Operating Lease, Payment to be Received, Year Five $1.85M.
- 2023-12-31: Lessor, Operating Lease, Payment to be Received, Year Five $1.70M.
| Period end | Lessor, Operating Lease, Payment to be Received, Year Five |
|---|---|
| 2024-12-31 | $1.85M 10-K · filed 2025-03-14 |
| 2023-12-31 | $1.70M 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |